Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
2.

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.

Flinn IW, Erter J, Daniel DB, Mace JR, Berdeja JG.

Oncologist. 2019 May 9. pii: theoncologist.2019-0286. doi: 10.1634/theoncologist.2019-0286. [Epub ahead of print]

PMID:
31073022
3.

Real time monitoring of water level and temperature in storage fuel pools through optical fibre sensors.

Rizzolo S, Périsse J, Boukenter A, Ouerdane Y, Marin E, Macé JR, Cannas M, Girard S.

Sci Rep. 2017 Aug 18;7(1):8766. doi: 10.1038/s41598-017-08853-7.

4.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, Catenacci D, Hsu JJ, Hack SP, Shames DS, Phan SC, Koeppen H, Cohn AL.

Oncologist. 2017 Mar;22(3):264-271. doi: 10.1634/theoncologist.2016-0223. Epub 2017 Feb 16.

5.

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).

Hainsworth JD, Reeves JA, Mace JR, Crane EJ, Hamid O, Stille JR, Flynt A, Roberson S, Polzer J, Arrowsmith ER.

Target Oncol. 2016 Oct;11(5):643-653.

PMID:
27154357
6.

Radiation effects on optical frequency domain reflectometry fiber-based sensor.

Rizzolo S, Marin E, Cannas M, Boukenter A, Ouerdane Y, Périsse J, Macé JR, Bauer S, Marcandella C, Paillet P, Girard S.

Opt Lett. 2015 Oct 15;40(20):4571-4. doi: 10.1364/OL.40.004571.

PMID:
26469566
7.

Radiation tolerant fiber Bragg gratings for high temperature monitoring at MGy dose levels.

Morana A, Girard S, Marin E, Marcandella C, Paillet P, Périsse J, Macé JR, Boukenter A, Cannas M, Ouerdane Y.

Opt Lett. 2014 Sep 15;39(18):5313-6. doi: 10.1364/OL.39.005313.

PMID:
26466259
8.

Vulnerability of OFDR-based distributed sensors to high γ-ray doses.

Rizzolo S, Boukenter A, Marin E, Cannas M, Perisse J, Bauer S, Mace JR, Ouerdane Y, Girard S.

Opt Express. 2015 Jul 27;23(15):18997-9009. doi: 10.1364/OE.23.018997.

PMID:
26367563
9.

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.

Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW.

Haematologica. 2015 May;100(5):670-6. doi: 10.3324/haematol.2014.119735. Epub 2015 Feb 20.

10.

Radioimmunotherapy in follicular lymphoma: an update.

Mace JR.

Clin Adv Hematol Oncol. 2012 Jun;10(6):394-6. No abstract available.

PMID:
22895242
11.

Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.

Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, Leu KM, Chandler WF, Baker LH.

J Clin Oncol. 2005 May 20;23(15):3597-604.

PMID:
15908670
12.

Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.

Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5829-34.

Supplemental Content

Support Center